Molecular imaging in the development of cancer therapeutics.
about
Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.Progesterone-targeted magnetic resonance imaging probesAffibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancerIsolated system towards a successful radiotherapy treatment.Imaging and cancer: a review.Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective studyPositron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis.[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.[18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.Functional PET imaging in cancer drug development.[(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in MiceForebrain ischemia-reperfusion simulating cardiac arrest in mice induces edema and DNA fragmentation in the brain.Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancerThe role of clinical imaging in oncological drug development.The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging.Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.Non-invasive molecular imaging for preclinical cancer therapeutic development.MicroSPECT and MicroPET Imaging of Small Animals for Drug DevelopmentDiagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.Molecular imaging with copper-64 in the drug discovery and development arena.Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.Evaluation of a dansyl-based amino acid DNSBA as an imaging probe for apoptosis detection.The preliminary study of 18F-FLT micro-PET/CT in predicting radiosensitivity of human nasopharyngeal carcinoma xenografts.Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.A new concept for cancer therapy: out-competing the aggressor.Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy.EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.State of the art in vivo imaging techniques for laboratory animals.Feasibility of state of the art PET/CT systems performance harmonisation.Is 18F-FDG PET/CT more reliable than 99mTc-MDP planar bone scintigraphy in detecting bone metastasis in nasopharyngeal carcinoma?Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?Comparison of F-NaF PET/CT and F-FDG PET/CT for Detection of Skull-Base Invasion and Osseous Metastases in Nasopharyngeal Carcinoma
P2860
Q30645097-20775068-F9B8-4FDC-BC4C-06C48DBB3635Q30836342-BA286E0A-A181-4E0F-80CC-8E5914F70A9BQ33279445-900465A5-9F12-4D50-B337-5B9B35BED67CQ33641143-E405B2F5-233E-403A-911F-7E6A6DA5616AQ33838696-8F547D33-1F60-42BD-A837-F48339924006Q34977050-49BD528D-8962-41C2-9CB8-B3D923C58E36Q35030360-6577AA3D-6841-4B2C-B004-AF9E26A5EA9AQ35613716-AA378DF1-B634-4DA2-A38B-46DDDD9DE66FQ35891382-95473B24-03DD-495F-8872-CFA1221DE85BQ36528174-DE81C2DE-00B0-45A9-B10C-07D4E2D44A34Q36768305-B35D2C42-E7B7-4BC4-B66D-13399B837885Q36900941-5231E2EF-49DC-4ED4-982E-49A1E461174DQ37101667-1104E297-C272-481B-94EB-28FBFFB7A20AQ37132173-451BA455-579B-48D1-8B03-4F27D0641337Q37187098-F0D1203A-BAA3-4357-B3B3-42E8FCF6C63DQ37190427-D68A4968-34AF-468A-900D-5695402FAE82Q37335099-96B27E73-521E-4F84-90E8-F0634A6C64FCQ37721526-B528E44E-D770-49CC-9639-7AB31E49F905Q38089102-46EA4A30-C489-4145-9FF6-17B138322013Q38166354-EF98657E-D973-4021-B6E0-8E1D6F80A9B1Q38391343-2A9FDE72-454E-4782-80F5-3615CB15A2F7Q38448424-66ECC666-1757-463F-9390-124F8292C7FFQ38720885-B19E2D23-8BB1-49BF-B091-0F46AA2F3096Q38919034-F6AF39AC-432F-457F-A629-A42336ED2839Q38957000-EFB5C4F7-C25C-460E-918F-4DFA64964A1CQ41573147-C2144124-9748-46FD-9F82-A91C6EA62618Q41843574-8A0DA650-4D1E-4333-AC6B-D0E9D2573EABQ42053570-D32529A0-4BDF-46E2-9D28-68BB22E96AECQ47388017-6060254A-ABC6-4373-AED2-07261992DC2DQ49833023-0B2554E3-8441-49C0-8A15-83BC7C9EC57BQ52676354-C0215D44-E3DC-4353-9797-35BE0FE0F941Q53076138-3703ACE1-3E9F-49C2-8634-9BA685933091Q53153694-E6676BC8-A422-43DB-AB06-67E542FEFB48Q58762716-AFA84145-F728-4154-AC05-C2D9B36883A4
P2860
Molecular imaging in the development of cancer therapeutics.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Molecular imaging in the development of cancer therapeutics.
@ast
Molecular imaging in the development of cancer therapeutics.
@en
type
label
Molecular imaging in the development of cancer therapeutics.
@ast
Molecular imaging in the development of cancer therapeutics.
@en
prefLabel
Molecular imaging in the development of cancer therapeutics.
@ast
Molecular imaging in the development of cancer therapeutics.
@en
P2093
P1476
Molecular imaging in the development of cancer therapeutics.
@en
P2093
Harvey R Herschman
Johannes Czernin
Wolfgang A Weber
P304
P356
10.1146/ANNUREV.MED.57.080904.190431
P577
2006-01-01T00:00:00Z